Impact of diabetes and chronic kidney disease on active surveillance outcomes for small renal masses: A cohort study

The American Cancer Society estimates 79,000 individuals will be diagnosed with kidney cancer in 2022, most of which are initially found as small renal masses (SRMs). Proper management of SRM patients includes careful evaluation of risk factors such as medical comorbidities and renal function. To investigate the importance of these risk factors, we examined their effect on crossover to delayed intervention (DI) and overall survival (OS) in patients undergoing active surveillance (AS) for SRMs. This is an Institutional Review Board-approved retrospective analysis of AS patients presented at kidney tumor conferences with SRMs between 2007 and 2017. Univariable and multivariable logistic regression analyses were performed to determine how factors including estimated glomerular filtration rate (eGFR), diabetes, and chronic kidney disease are associated with DI and OS. A total of 111 cases were reviewed. In general, AS patients were elderly and had significant comorbidities. On univariate analysis, intervention was more likely to occur in patients with a younger age ( = 0.01), better kidney function ( = 0.01), and higher tumor growth rates (GRs) ( = 0.02). Higher eGFR was associated with better survival ( = 0.03), while higher tumor GRs ( = 0.014), greater Charlson Comorbidity Index ( = 0.01), and larger tumors ( = 0.01) were associated with worse OS. Of the comorbidities, diabetes was found to be an independent predictor of worse OS ( = 0.01). Patient-level factors - such as diabetes and eGFR - are associated with the rate of DI and OS among SRM patients. Consideration of these factors may facilitate better AS protocols and improve patient outcomes for those with SRMs.